Han Hui-Jie, Lu Yue-Wu, Xia Rui-Xiang
Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui Province, China.
Department of Hematology & Endocrinology, Huaibei People's Hospital, Huaibei 235000, Anhui Province, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016 Feb;24(1):25-9. doi: 10.7534/j.issn.1009-2137.2016.01.005.
To explore the clinical efficacy and safety of rituximab combined with fludarabine and cyclophosphamide for the treatment of the chronic lymphocytic leukemia (CLL).
Forty cases of CLL patients treated in our hospital from March 2010 to March 2014 years were selected and divided into the observation group (20 cases) and control group (20 cases) by random number table method. The patients in control group were treated with CHOP chemotherapy, the patients in observation group were treated with rituximab combined with fludarabine, cyclophosphamide treatment. The therapeutic efficacy of patients in 2 groups was analyzed according to the peripheral hemogram indexes, symptom and sign disappeared time as well as adverse reaction incidence.
the remission rate in observation group was 90.00%, which was significantly higher than that in control group (70.00%) (P < 0.05); the peripheral hemogram indexes in 2 groups before treatment showed no significant difference (P > 0.05), and were significantly improved after treatment, but the white blood cell count and lymphocyte absolute number were significantly lower in observation group as compared to the control group (P < 0.05); symptom and sign disappeared time in observation group were significantly shorter as compared with the control group (P < 0.05); adverse reaction incidence in obseovation group was significantly lower as compared with control group (P < 0.05).
application of rituximab combined with fludarabine and cyclophosphamide in the treatment of CLL shows the higher curative effect, can effectively improve the symptoms and reduce the incidence of adverse reactions. It is worthy to be popularized.
探讨利妥昔单抗联合氟达拉滨及环磷酰胺治疗慢性淋巴细胞白血病（CLL）的临床疗效及安全性。
选取2010年3月至2014年3月在我院治疗的40例CLL患者，采用随机数字表法分为观察组（20例）和对照组（20例）。对照组采用CHOP化疗，观察组采用利妥昔单抗联合氟达拉滨、环磷酰胺治疗。根据外周血常规指标、症状体征消失时间及不良反应发生率分析两组患者的治疗效果。
观察组缓解率为90.00%，显著高于对照组（70.00%）（P<0.05）；两组治疗前外周血常规指标差异无统计学意义（P>0.05），治疗后均显著改善，但观察组白细胞计数及淋巴细胞绝对值低于对照组（P<0.05）；观察组症状体征消失时间显著短于对照组（P<0.05）；观察组不良反应发生率显著低于对照组（P<0.05）。
利妥昔单抗联合氟达拉滨及环磷酰胺治疗CLL疗效较高，能有效改善症状，降低不良反应发生率，值得推广。
